Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 10/20 | 0.53 |
| ▸ | BRAF | P15056 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 2/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL527402 | 0.85 | CYP17A1 (0.58) | CYP17A1KMT2ANAMPT | |
| SCHEMBL527118 | 0.82 | TSHR (0.61) | CYP17A1KMT2ATSHR | |
| SCHEMBL526959 | 0.80 | CYP17A1 (0.59) | CYP17A1BRAF | |
| SCHEMBL527052 | 0.79 | CYP17A1 (0.57) | CYP17A1KMT2A | |
| SCHEMBL526355 | 0.79 | CYP17A1 (0.57) | CYP17A1 | |
| SCHEMBL527415 | 0.78 | CYP17A1 (0.59) | CYP17A1NAMPT | |
| SCHEMBL527150 | 0.77 | CYP17A1 (0.57) | CYP17A1BRAF | |
| SCHEMBL526615 | 0.76 | CYP17A1 (0.73) | CYP17A1KMT2ASYKNAMPT | |
| SCHEMBL527022 | 0.75 | CYP17A1 (0.57) | CYP17A1TSHR | |
| SCHEMBL526958 | 0.75 | CYP17A1 (0.55) | CYP17A1BRAFNAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2598481-B1 | SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-08-31 | — | — | EP | claimed |
| US-8916553-B2 | Sulfonamide compounds useful as CYP17 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-23 | — | — | US | claimed |
| US-20140148453-A1 | SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-05-29 | — | — | US | claimed |
| EP-2598481-A1 | SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS | Bristol-Myers Squibb Company (US) | 2013-06-05 | — | — | EP | claimed |
| WO-2012015723-A1 | SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-02 | — | — | WO | claimed |
| EP-2598481-B1 | SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-08-31 | — | — | EP | disclosed |
| EP-2598481-B1 | SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-08-31 | — | — | EP | disclosed |
| US-8916553-B2 | Sulfonamide compounds useful as CYP17 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-23 | — | — | US | disclosed |
| US-8916553-B2 | Sulfonamide compounds useful as CYP17 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-23 | — | — | US | disclosed |
| US-8916553-B2 | Sulfonamide compounds useful as CYP17 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-23 | — | — | US | disclosed |
| US-20140148453-A1 | SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-05-29 | — | — | US | disclosed |
| US-20140148453-A1 | SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-05-29 | — | — | US | disclosed |
| US-20140148453-A1 | SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-05-29 | — | — | US | disclosed |
| EP-2598481-A1 | SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS | Bristol-Myers Squibb Company (US) | 2013-06-05 | — | — | EP | disclosed |
| WO-2012015723-A1 | SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-02 | — | — | WO | disclosed |
| WO-2012015723-A1 | SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148453-A1 | SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS | SULT1A1, SULT2A1, SULT1E1 | CYP17A1 28/4885BRAF 479/4885KMT2A 1896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.